相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer
Koichi Sakaguchi et al.
ANTICANCER RESEARCH (2018)
Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers
Yasutaka Tono et al.
Oncotarget (2018)
Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
Alexey A. Larionov
FRONTIERS IN ONCOLOGY (2018)
Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy
Ander Urruticoechea et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study
L. M. Smyth et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance
Kenichi Inoue et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results
Edith A. Perez et al.
BREAST CANCER RESEARCH (2016)
Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring
Andrew McGuire et al.
CANCER AND METASTASIS REVIEWS (2015)
Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Chau Dang et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Peter A. Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review
Junichiro Watanabe
SPRINGERPLUS (2015)
Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy
Mark K. Doherty et al.
INTERNATIONAL JOURNAL OF WOMENS HEALTH (2015)
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
Chris Twelves et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer
Kristi McIntyre et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors
M. Koczywas et al.
BRITISH JOURNAL OF CANCER (2014)
Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer
Sharon Wilks et al.
CLINICAL BREAST CANCER (2014)
Presentation and management of docetaxel-related adverse effects in patients with breast cancer
Maria Y. Ho et al.
CANCER MANAGEMENT AND RESEARCH (2014)
Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy
Linda T. Vahdat et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
Sandra M. Swain et al.
LANCET ONCOLOGY (2013)
A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer
K. Aogi et al.
ANNALS OF ONCOLOGY (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortes et al.
LANCET (2011)
Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group
Kenichi Inoue et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine
Javier Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Linda T. Vahdat et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Peripheral neuropathy induced by microtubule-stabilizing agents
JJ Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group
M Marty et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
